Assignee
SEAGEN INC
US·57 granted patents·127 pending applications·79 citations·filing 2011–2025
Top patents by PatentIndex Score
184 records- 0196US11077164B2Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugatesSEAGEN INC·Filed 2021·Granted Aug 3, 2021·3 cites·18 claims
- 0296US10940178B2Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugatesSEAGEN INC·Filed 2020·Granted Mar 9, 2021·4 cites·30 claims
- 0395US11510959B2Hydrophilic antibody-drug conjugatesSEAGEN INC·Filed 2021·Granted Nov 29, 2022·3 cites·11 claims
- 0495US11369658B2Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugatesSEAGEN INC·Filed 2021·Granted Jun 28, 2022·2 cites·9 claims
- 0595US11078291B2BCMA antibodies and use of same to treat cancer and immunological disordersSEAGEN INC·Filed 2019·Granted Aug 3, 2021·8 cites·66 claims
- 0695US10912813B2Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugatesSEAGEN INC·Filed 2018·Granted Feb 9, 2021·5 cites·1 claims
- 0792US10933112B2Hydrophilic antibody-drug conjugatesSEAGEN INC·Filed 2015·Granted Mar 2, 2021·5 cites·24 claims
- 0891US2024415917A1Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugatesSEAGEN INC·Filed 2024·Application pending·0 cites
- 0989US11767365B2BCMA antibodies and use of same to treat cancer and immunological disordersSEAGEN INC·Filed 2021·Granted Sep 26, 2023·1 cites·73 claims
- 1089US11666572B2Treatment of HER2 positive cancersSEAGEN INC·Filed 2021·Granted Jun 6, 2023·2 cites·23 claims
- 1189US11207324B2Treatment of HER2 positive cancersSEAGEN INC·Filed 2018·Granted Dec 28, 2021·6 cites·53 claims
- 1288US12036286B2Selective drug release from internalized conjugates of biologically active compoundsSEAGEN INC·Filed 2022·Granted Jul 16, 2024·2 cites·12 claims
- 1388US11319526B2Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylationSEAGEN INC·Filed 2019·Granted May 3, 2022·2 cites·63 claims
- 1488US2024252672A1Beta-glucuronide-linker drug conjugatesSEAGEN INC·Filed 2023·Application pending·0 cites
- 1586US11103593B2Pegylated drug-linkers for improved ligand-drug conjugate pharmacokineticsSEAGEN INC·Filed 2014·Granted Aug 31, 2021·13 cites·26 claims
- 1686US2024190981A1Humanized Anti-CD70 Binding Agents and Uses ThereofSEAGEN INC·Filed 2023·Application pending·0 cites
- 1785USRE48959EHumanized antibodies to LIV-1 and use of same to treat cancerSEAGEN INC·Filed 2011·Granted Mar 8, 2022·4 cites·124 claims
- 1885US2024139275A1Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugatesSEAGEN INC·Filed 2022·Application pending·0 cites
- 1984US12257281B2Hydrophilic antibody-drug conjugatesSEAGEN INC·Filed 2023·Granted Mar 25, 2025·0 cites·6 claims
- 2084US11559558B2Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugatesSEAGEN INC·Filed 2022·Granted Jan 24, 2023·0 cites·30 claims
- 2184US2024247059A1Humanized antibodies to liv-1 and use of same to treat cancerSEAGEN INC·Filed 2023·Application pending·0 cites
- 2284US2024109975A1Bcma antibodies and use of same to treat cancer and immunological disordersSEAGEN INC·Filed 2023·Application pending·0 cites
- 2383US12496353B2Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathwaySEAGEN INC·Filed 2023·Granted Dec 16, 2025·0 cites·13 claims
- 2483US11116847B2Methylene carbamate linkers for use with targeted-drug conjugatesSEAGEN INC·Filed 2014·Granted Sep 14, 2021·3 cites·53 claims
- 2583US11028181B2Glycan-interacting compounds and methods of useSEAGEN INC·Filed 2016·Granted Jun 8, 2021·3 cites·93 claims
- 2682US11202827B2Dosage and administration of non-fucosylated anti-CD40 antibodiesSEAGEN INC·Filed 2017·Granted Dec 21, 2021·2 cites·170 claims
- 2781US11844839B2Process for the preparation of pegylated drug-linkers and intermediates thereofSEAGEN INC·Filed 2017·Granted Dec 19, 2023·2 cites·26 claims
- 2881US2024084031A1Variant target binding agents and uses thereofSEAGEN INC·Filed 2022·Application pending·0 cites
- 2981US2024075134A1Dosage and administration of non-fucosylated anti-cd40 antibodySEAGEN INC·Filed 2023·Application pending·0 cites
- 3081US2023242648A1Antibodies to integrin avb6 and use of same to treat cancerSEAGEN INC·Filed 2023·Application pending·0 cites
- 3180US2024075135A1Dosage and administration of non-fucosylated anti-cd40 antibodiesSEAGEN INC·Filed 2023·Application pending·0 cites
- 3280US2023055475A1Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylationSEAGEN INC·Filed 2022·Application pending·0 cites
- 3379US11541128B2Multi-drug antibody drug conjugatesSEAGEN INC·Filed 2017·Granted Jan 3, 2023·2 cites·15 claims
- 3479US2023201344A1Dosage and administration of non-fucosylated anti-cd40 antibodySEAGEN INC·Filed 2022·Application pending·0 cites
- 3579US2023033859A1Cd19 binding agents and uses thereofSEAGEN INC·Filed 2022·Application pending·0 cites
- 3678US2023201343A1Dosage and administration of non-fucosylated anti-cd40 antibodiesSEAGEN INC·Filed 2022·Application pending·0 cites
- 3778US2022143209A1Beta-glucuronide-linker drug conjugatesSEAGEN INC·Filed 2021·Application pending·0 cites
- 3878US2023132738A1Hydrophilic antibody-drug conjugatesSEAGEN INC·Filed 2022·Application pending·0 cites
- 3978US2023105802A1Anti-ntb-a antibodies and related compositions and methodsSEAGEN INC·Filed 2022·Application pending·0 cites
- 4078US2022265822A1Dosage and administration of non-fucosylated anti-cd40 antibodySEAGEN INC·Filed 2022·Application pending·0 cites
- 4177US12048698B2Treatment of HER2 positive cancersSEAGEN INC·Filed 2023·Granted Jul 30, 2024·0 cites·19 claims
- 4277US11819553B2Glypican 3 antibodies and conjugates thereofSEAGEN INC·Filed 2019·Granted Nov 21, 2023·1 cites·21 claims
- 4377US11730822B2Process for the preparation of glucuronide drug-linkers and intermediates thereofSEAGEN INC·Filed 2018·Granted Aug 22, 2023·1 cites·48 claims
- 4477US2024325561A1Pegylated drug-linkers for improved ligand-drug conjugate pharmacokineticsSEAGEN INC·Filed 2024·Application pending·0 cites
- 4577US2022249662A1Dosage and administration of non-fucosylated anti-cd40 antibodiesSEAGEN INC·Filed 2022·Application pending·0 cites
- 4676US11401339B2Anti-TIGIT antibodiesSEAGEN INC·Filed 2019·Granted Aug 2, 2022·1 cites·122 claims
- 4776US11033561B2Methods of inhibition of protein fucosylation in vivo using fucose analogsSEAGEN INC·Filed 2019·Granted Jun 15, 2021·0 cites·17 claims
- 4876US2023391848A1Selective reduction of proteinsSEAGEN INC·Filed 2023·Application pending·0 cites
- 4976US2024343826A1Compositions and Methods for Targeting Cancer Stem CellsSEAGEN INC·Filed 2023·Application pending·0 cites
- 5075US12268751B2Anti-αVβ6 antibodies and antibody-drug conjugatesSEAGEN INC·Filed 2023·Granted Apr 8, 2025·0 cites·15 claims
Showing the top 50 of 184 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →